2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH DENA BATTLE
Patient Perspectives on Cytoreductive Nephrectomy after the CARMENA Trial

VIEW ALL ASCO GU 2019 VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH OLIVER SARTOR
Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer

VIEW ALL PCF VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH KARIM FIZAZI
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC

VIEW ALL ASCO GU 2019 VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH JAMES GULLEY
Immunotherapy Across Genitourinary Malignancies

VIEW ALL ASCO GU 2019 VIDEOS

Featured Videos

#AUA14 - State-of-the-Art Lecture: Clinical implications of The Cancer Genome Atlas Project on muscle-invasive bladder cancer - Session Highlights

ORLANDO, FL USA (UroToday.com) - Dr. Seth Lerner from Baylor College of Medicine presented his group’s findings from The Cancer Genome Atlas (TCGA) project. TCGA projects are the comprehensive description and integrated analysis of somatic mutations and expression profiling including mRNA, protein, and methylation for every individual tumor. As part of the TCGA bladder project, DNA from 131 muscle-invasive urothelial bladder cancer tumors and corresponding normal samples were analyzed. It was reported that with every tumor, on average, 302 exonic mutations, 204 segmental alterations in DNA copy, and 22 genomic alterations were seen. Moreover, 32 recurrent significantly mutated genes were identified which were involved in bladder cancer pathogenesis.

 

auaMoreover, roughly 69% of tumors had at least 1 “significantly mutated gene” or SMG, suggesting a strategy for personalized targeted therapy in most of the patients with invasive, high-grade bladder cancer. Several altered genes were identified as potential therapeutic targets for patients with advanced urothelial carcinoma (UC) (e.g., PIK3CA, ERBB2, FGFR3, TSC1, ERBB3). By single-nucleotide polymorphism arrays, multiple areas of somatic copy number alterations (SCNAs) were identified, with CDKN2A deletion being the most common one (47%). Although the role of viral infection in the pathogenesis of UC remains unclear, viral DNA (cytomegalovirus, human herpes virus 6B, human papilloma virus-16, or BK polyomavirus), was identified in 6% and viral transcripts were identified in 4% (CMV, BK polyoma virus, HPV16). Furthermore, integrated analysis revealed that multiple pathways are recurrently altered in UC, including cell cycle regulation (93%), kinase and PI3-K signaling (72%), and epigenetic regulators (such as: histone modifying genes (89%); SWI/SNF nucleosome remodeling complex ( 64%)).

As a result of these interesting findings, the scientists involved with this project concluded that bladder cancer is one of the most highly mutated tumor types, similar to lung cancer, breast cancer, and melanoma. These findings suggest that perhaps already FDA-approved drugs that are effective in these other tumor types could potentially be effective in urothelial cancers that share the same molecular phenotype(s). The major take-home point from TCGA project is that the majority of patients with MIBC have some sorts of actionable mutations and that epigenetic regulatory genes are frequently altered in this type of bladder cancer, suggesting that there may be a different paradigm for therapeutic intervention. More basic science and clinical research, as well as assistance from biotech and pharmaceutical companies, are needed to identify drugs that target these alterations.

The amount of work that TCGA group has put into this project is tremendous, and the cooperation by the team of almost 300 authors is a monumental achievement. Their work should be highly regarded for the many novel findings described.

Presented by Seth P. Lerner, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Baylor College of Medicine, Houston, TX USA

Written by Reza Mehrazin, MD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 3 Issue 4

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe